Complement Therapeutics is an early stage biotechnology company developing innovative medicines that are caused by dysregulation of the complement system, a key part of our immune system.

Their lead product, CTx001, is a gene therapy that is being developed for the potential treatment of geographic atrophy, a form of age related macular degeneration, a leading cause of blindness. CTx001 is currently in early stage development with plans to initiate clinical trials in 2025.

Complement Therapeutics is also developing a novel technology platform, the Complement Precision Medicine (CPM) platform that has the ability to measure several proteins within the complement system to enable better diagnosis and monitoring of disease.

Complement Therapeutics successfully raised a Series A financing of €72m in April 2023 to support the development of its innovative pipeline.

Complement Therapeutics chose to locate its laboratory facilities at SBC to benefit from the leading biotechnology ecosystem that has developed there with close proximity to and the opportunity to engage with potential partners and other biotech companies.